☆ 4.7 Meeting Abstract

Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

ANNALS OF ONCOLOGY (2022)

Get Full Text
Add to Collection

Journal

ANNALS OF ONCOLOGY
Volume 33, Issue 7, Pages S1401-S1401

Publisher

ELSEVIER
DOI: 10.1016/j.annonc.2022.08.031

Keywords

-

Categories

Oncology

Funding

  1. Eisai Inc., Nutley, NJ, USA
  2. Merck Sharp Dohme LLC

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.